• Je něco špatně v tomto záznamu ?

Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion

R. Pallavi, E. Gatti, T. Durfort, M. Stendardo, R. Ravasio, T. Leonardi, P. Falvo, BA. Duso, S. Punzi, A. Xieraili, A. Polazzi, D. Verrelli, D. Trastulli, S. Ronzoni, S. Frascolla, G. Perticari, M. Elgendy, M. Varasi, E. Colombo, M. Giorgio, L....

. 2024 ; 15 (1) : 828. [pub] 20240127

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007496

Caloric Restriction (CR) has established anti-cancer effects, but its clinical relevance and molecular mechanism remain largely undefined. Here, we investigate CR's impact on several mouse models of Acute Myeloid Leukemias, including Acute Promyelocytic Leukemia, a subtype strongly affected by obesity. After an initial marked anti-tumor effect, lethal disease invariably re-emerges. Initially, CR leads to cell-cycle restriction, apoptosis, and inhibition of TOR and insulin/IGF1 signaling. The relapse, instead, is associated with the non-genetic selection of Leukemia Initiating Cells and the downregulation of double-stranded RNA (dsRNA) sensing and Interferon (IFN) signaling genes. The CR-induced adaptive phenotype is highly sensitive to pharmacological or genetic ablation of LSD1, a lysine demethylase regulating both stem cells and dsRNA/ IFN signaling. CR + LSD1 inhibition leads to the re-activation of dsRNA/IFN signaling, massive RNASEL-dependent apoptosis, and complete leukemia eradication in ~90% of mice. Importantly, CR-LSD1 interaction can be modeled in vivo and in vitro by combining LSD1 ablation with pharmacological inhibitors of insulin/IGF1 or dual PI3K/MEK blockade. Mechanistically, insulin/IGF1 inhibition sensitizes blasts to LSD1-induced death by inhibiting the anti-apoptotic factor CFLAR. CR and LSD1 inhibition also synergize in patient-derived AML and triple-negative breast cancer xenografts. Our data provide a rationale for epi-metabolic pharmacologic combinations across multiple tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007496
003      
CZ-PrNML
005      
20240423160016.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-023-44348-y $2 doi
035    __
$a (PubMed)38280853
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pallavi, Rani $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000257209150
245    10
$a Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion / $c R. Pallavi, E. Gatti, T. Durfort, M. Stendardo, R. Ravasio, T. Leonardi, P. Falvo, BA. Duso, S. Punzi, A. Xieraili, A. Polazzi, D. Verrelli, D. Trastulli, S. Ronzoni, S. Frascolla, G. Perticari, M. Elgendy, M. Varasi, E. Colombo, M. Giorgio, L. Lanfrancone, S. Minucci, L. Mazzarella, PG. Pelicci
520    9_
$a Caloric Restriction (CR) has established anti-cancer effects, but its clinical relevance and molecular mechanism remain largely undefined. Here, we investigate CR's impact on several mouse models of Acute Myeloid Leukemias, including Acute Promyelocytic Leukemia, a subtype strongly affected by obesity. After an initial marked anti-tumor effect, lethal disease invariably re-emerges. Initially, CR leads to cell-cycle restriction, apoptosis, and inhibition of TOR and insulin/IGF1 signaling. The relapse, instead, is associated with the non-genetic selection of Leukemia Initiating Cells and the downregulation of double-stranded RNA (dsRNA) sensing and Interferon (IFN) signaling genes. The CR-induced adaptive phenotype is highly sensitive to pharmacological or genetic ablation of LSD1, a lysine demethylase regulating both stem cells and dsRNA/ IFN signaling. CR + LSD1 inhibition leads to the re-activation of dsRNA/IFN signaling, massive RNASEL-dependent apoptosis, and complete leukemia eradication in ~90% of mice. Importantly, CR-LSD1 interaction can be modeled in vivo and in vitro by combining LSD1 ablation with pharmacological inhibitors of insulin/IGF1 or dual PI3K/MEK blockade. Mechanistically, insulin/IGF1 inhibition sensitizes blasts to LSD1-induced death by inhibiting the anti-apoptotic factor CFLAR. CR and LSD1 inhibition also synergize in patient-derived AML and triple-negative breast cancer xenografts. Our data provide a rationale for epi-metabolic pharmacologic combinations across multiple tumors.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a kalorická restrikce $7 D031204
650    12
$a akutní myeloidní leukemie $x patologie $7 D015470
650    _2
$a histondemethylasy $x genetika $7 D056466
650    _2
$a nádorové kmenové buňky $x patologie $7 D014411
650    12
$a inzuliny $7 D061385
650    _2
$a nádorové buněčné linie $7 D045744
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gatti, Elena $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Durfort, Tiphanie $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0009000709261185
700    1_
$a Stendardo, Massimo $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Ravasio, Roberto $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000231440514
700    1_
$a Leonardi, Tommaso $u Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Milan, Italy $1 https://orcid.org/0000000244491863
700    1_
$a Falvo, Paolo $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Duso, Bruno Achutti $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000248396038
700    1_
$a Punzi, Simona $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Xieraili, Aobuli $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Polazzi, Andrea $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Verrelli, Doriana $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000157646775
700    1_
$a Trastulli, Deborah $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000324073290
700    1_
$a Ronzoni, Simona $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Frascolla, Simone $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Perticari, Giulia $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000293689657
700    1_
$a Elgendy, Mohamed $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $u Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany $u Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany $u Mildred-Scheel Early Career Center, National Center for Tumor Diseases Dresden (NCT/UCC) University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, CZ-14220, Czech Republic
700    1_
$a Varasi, Mario $u IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy
700    1_
$a Colombo, Emanuela $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $u Department of Hemato-Oncology, Universita' Statale di Milano, Milan, Italy $1 https://orcid.org/0000000320797398
700    1_
$a Giorgio, Marco $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $u Department of Biomedical Sciences, University of Padova, Padova, Italy
700    1_
$a Lanfrancone, Luisa $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $1 https://orcid.org/0000000245233815
700    1_
$a Minucci, Saverio $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy $u Department of Hemato-Oncology, Universita' Statale di Milano, Milan, Italy
700    1_
$a Mazzarella, Luca $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. luca.mazzarella@ieo.it $1 https://orcid.org/0000000240433279
700    1_
$a Pelicci, Pier Giuseppe $u Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. piergiuseppe.pelicci@ieo.it $u Department of Hemato-Oncology, Universita' Statale di Milano, Milan, Italy. piergiuseppe.pelicci@ieo.it $1 https://orcid.org/0000000250762316
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 15, č. 1 (2024), s. 828
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38280853 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160012 $b ABA008
999    __
$a ok $b bmc $g 2081473 $s 1217263
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c 1 $d 828 $e 20240127 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace